Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.5.1.1 (
DNA ligase
)
2,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Drosophila melanogaster contains DNA ligases I and II. The activity of DNA ligase I is especially high during early embryonic periods, but decreases rapidly afterwards. Although the activity of
DNA ligase
II is low, it persists throughout all developmental stages. The specific activity of
DNA ligase
II is high in embryos, but the total activity per body mass was highest in pupae. To characterize the properties of
DNA ligase
II further and to clarify its differences from DNA ligase I,
DNA ligase
II was prepared from pupae of D. melanogaster. The enzyme was purified about 3200-fold by ammonium sulfate fractionation (40-70% saturation), phosphocellulose (
P11
) and Ultrogel column chromatography. Some of the properties have been reported previously. The isoelectric point of
DNA ligase
II was 6.4 while those of DNA ligase I were 4.9 and 5.8. The optimum pH of
DNA ligase
II was 7.8-8.1 but 8.0-8.5 for DNA ligase I. The molecular masses of
DNA ligase
II adducts with AMP were determined as 90 and 70 kDa. These adducts were degraded to 42 and 14.4 kDa by trypsin digestion. For preparation of monoclonal antibodies, a mouse was immunized with the purified enzyme. Two clones, 10-6 and 3-3 IgM, were obtained and purified from mouse ascites. These antibodies showed both binding and neutralizing activities toward
DNA ligase
II from D. melanogaster, but did not react with DNA ligase I from the same origin. These results showed clearly that DNA ligases I and II have different properties and suggest they have different roles during the developmental stages of D. melanogaster.
...
PMID:Purification and characterization of DNA ligase II from Drosophila melanogaster. 212 58
